Clinical Trial Search

Primary: Effect of TIVA With Ketofol and Ketofol Plus Lidocaine on Extubation Time in Children — 240; 120 second

Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) Between VX-150 Versus Placebo as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 24 Hours After the First…

Primary: Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours — 62.5; 42.5; 65.8; 65.8…

Primary: Percentage of Patients With Complete Tumor Regression Rate (TRG1) — 12.5; 50 percentage of participants

Primary: Maximum Tolerated Dose (MTD) in Participants With Any Solid Tumor (Phase Ib) — 1.4; 600 milligrams per square meter (mg/m2)

Primary: Safety of a Single High-dose of Oral Cholecalciferol to Treat a Vitamin D Deficiency in Children With Cystic Fibrosis — 9.57; 9.47 mg/dL

Primary: Complete Response Rate — 19 Participants

Primary: Provocative Concentration (PC20) After Methacholine Challenge — 0.91; 0.84; 0.82 log [mg/mL] — p=0.616

Primary: Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel — 1 Participants

Primary: Stem Cell Mobilization Success Rate With Cytarabine and Rituximab — 4 Participants

Primary: Average Visual Analog Scale at Baseline — 7.92; 7.88 Units on a scale

Primary: Objective Response Rate (ORR) Determined by Clinical Palpation — 58.9; 53.8 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of Ra-223 Dichloride in Osteosarcoma — 100; 100 kBq/kg

Primary: Change From Parent Study (A4091003 [NCT00545129]) Baseline in Brief Pain Inventory-Short Form (BPI-sf) Average Pain Score for at Weeks 4, 8, 16, 24, 40, 48, 56 and 64…

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants